Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2022-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（余海宗）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report or results announcement, no mention of voting results, no legal proceedings, no capital changes, and no earnings information. The document is a declaration related to board/management changes, specifically the nomination of a board member. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2022-04-28 Chinese
独立董事提名人声明（刘泽武）
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report or results, no meeting materials, and no voting results. This is a corporate governance-related announcement about board composition, specifically about director nomination. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused solely on nomination, not a full report or announcement of voting results.
2022-04-28 Chinese
独立董事候选人声明（刘泽武）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, Liu Zewu, confirming qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director of Chengdu Lead Drug Development Co., Ltd. It includes detailed personal qualifications, legal references, and commitments related to the director role. There are no financial statements, audit information, or report data. This is a governance-related disclosure about board membership qualifications and independence, not a report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management nomination and qualifications, confirming the classification.
2022-04-28 Chinese
成都先导药物开发股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Chengdu Lead Drug Development Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the amount, types of financial products, investment purpose, decision-making process, and regulatory compliance related to the use of idle raised funds. The document references regulatory approvals, board and supervisory committee meetings, independent director opinions, and compliance with listing rules and regulatory guidelines. It does not contain financial statements or quarterly/yearly financial results but is a disclosure about the company's capital management activities related to raised funds. This fits the category of Capital/Financing Update (CAP), as it updates on the company's use of capital raised through fundraising and its management of those funds.
2022-04-28 Chinese
成都先导药物开发股份有限公司关于变更募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Chengdu Lead Drug Development Co., Ltd. regarding changes to the investment projects funded by raised capital. It discusses modifications in project locations, total investment amounts, investment structures, and implementation timelines. The document includes financial figures related to the raised funds, project descriptions, risk assessments, and approvals from the board, independent directors, supervisory board, and the sponsor institution. It references regulatory approvals and compliance with securities regulations. The content focuses on the use and management of raised funds and changes to investment projects rather than presenting financial statements or earnings results. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising investment projects and capital usage changes.
2022-04-28 Chinese
成都先导药物开发股份有限公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or financial statement. There is no indication that this is an announcement or a brief summary; the document contains substantive content about internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, including internal control evaluations. The document length is 4013 characters, which is sufficient for a detailed report but not overly brief to be an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.